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Background. Asymmetric dimethylarginine (ADMA) is associated with macrovascular disease and possibly with microangiopathy
in type 2 diabetes (T2DM). We tested the hypothesis that ADMA is related to diabetic retinopathy (DR) independently of
macrovascular disease. Methods. This cross-sectional study included 127 T2DM patients selected to achieve equal distributions
of patients with and without macrovascular disease in the groups with and without DR. Results. Patients with DR had increased
ADMA, longer diabetes duration, and reduced glomerular ﬁltration rate (GFR). ADMA correlated with GFR (ρ =− 0.35;
P<. 001),diabetes duration (ρ = 0.19;P = .048),and age(ρ = 0.19;P = .033).Logisticregression analysisrevealed anassociation
ofADMAwithDR. After adjustmentformacrovasculardisease,thisassociationremainedsigniﬁcant(OR1.48;95%CI:1.02–2.15;
P = .039). Inclusion of GFR and T2DM duration into the model abolished this signiﬁcant relationship. GFR remained the only
independent predictor for DR. A 10mL/min/1.73m2 GFR decrease was associated with DR in a multivariate model (OR 1.30;
95% CI:1.08–1.56; P = .006). Conclusions. These ﬁndings indicate an association between ADMA and DR in T2DM independent
of macrovascular disease. This relationship is modiﬁed by GFR, the only parameter signiﬁcantly related to DR in multivariate
analysis.
1.Introduction
Hyperglycemia is closely linked to the risk of microvascular
complications in diabetes [1]. Patients suﬀering from type 2
diabetes (T2DM) and diabetic retinopathy are at increased
risk for developing cardiovascular disease [1–3]. Asymmet-
ric dimethylarginine (ADMA), an endogenous competitive
nitric oxide synthase inhibitor, is an emerging risk marker
for future cardiovascular events in diﬀerent patient groups
including patients with T2DM [4]. In addition to its
relation to macrovascular complications, ADMA has also
been linked to the development of diabetic microvascular
complications. ADMA is elevated in patients with type 1
and type 2 diabetes with diabetic nephropathy and predicts
renal impairment in these patients [5–7]. Malecki et al.
found increased ADMA concentrations in subjects with
T2DM and diabetic retinopathy [8]. However, it remained
unclear if macrovascular disease which was associated with
signiﬁcantly elevated circulating ADMA in previous reports
inﬂuenced this relationship. The current study was planned2 Cardiology Research and Practice
to test the hypothesis that ADMA is associated with diabetic
retinopathy independently of macrovascular disease and
other possible confounders.
2.Materialsand Methods
This study was conducted in accordance with the guidelines
of the Declaration of Helsinki and the institutional ethics
committee. It was designed as a cross-sectional study.
One hundred twenty seven patients with T2DM who
referred to a specialty outpatient diabetic clinic between
September 2003 and March 2004 were included. All patients
were suﬀering from T2DM according to the American
Diabetes Association criteria and were on stable antidiabetic
treatment for at least 6 months. All patients were treated
according to the Guidelines of the American Diabetes
Association. At the time of inclusion, demographic and
anthropometric data, clinical characteristics, and current
medication of all patients were recorded with special
attention to present cardiovascular risk factors and co-
morbidities. Patients were selected with regard to prevalent
retinopathy and macrovascular disease to reach a proportion
of around 50% patients with retinopathy and 50% patients
with macrovascular disease equally distributed between the
retinopathy and the no retinopathy group.
Demographic data and medical history including age,
sex, smoking habits, hyperlipidemia, arterial hypertension,
coronary artery disease, history of myocardial infarction,
and stroke were assessed in all patients. The presence of
macrovascular disease was conﬁrmed by hospital records.
The study included 60 patients with and 67 patients without
diabetic retinopathy. Macrovascular disease was present
in 38 patients with and in 30 patients without diabetic
retinopathy.Body massindex(BMI)wascalculatedasweight
divided by squared height. Blood pressure was determined
in all subjects at rest. Arterial hypertension was diagnosed
if resting blood pressure values were >140/90mmHg or
patientsweretakingantihypertensive drugs.Allpatientswere
staged for the presence of diabetic retinopathy according to
the Early Treatment of Diabetic Retinopathy Study (ETDRS)
classiﬁcation [9–11]. Patients who had retinal abnormalities
otherthandiabeticretinopathyorwhounderwentpanretinal
laser treatment, vitrectomy, or anti-VEGF therapy in the
past 12 months were excluded. Before retinal photography,
the patient’s pupils were dilated with tropicamide 1%; this
procedure was repeated if the pupils did not reach at least
5mm in diameter. Color retinal slides with a suitable 40◦
retinal camera were taken of two ﬁelds in both eyes. For the
central ﬁeld, the centerof theopticdisc was positioned at the
nasal end of the horizontal meridian of the ﬁeld of view; for
the nasal ﬁeld, the optic disc was positioned 1 disc diameter
from the temporal edge of the ﬁeld on the horizontal
meridian. Two pseudostereoscopic images with a horizontal
shift of 3◦ to 5◦ were then taken of each ﬁeld in both eyes,
resulting in eight images of each patient. The overlap of
the ﬁelds recorded a retinal view of approximately 75◦
horizontally by 40◦ vertically; therefore, clinically signiﬁcant
lesions of diabetic retinopathy were easily detectable. Slides
were separately screened by two experienced graders in the
same center, according to a validated protocol [12].
2.1. Laboratory Investigations. Venous blood was drawn after
an overnight fast for the determinationof ADMA,SDMA,L-
arginine, and routine parameters. Blood levels of creatinine,
HbA1c, total cholesterol, HDL-cholesterol, LDL-cholesterol,
triglycerides, and high-sensitivity C-reactive protein (CRP)
were measured by standard laboratory methods in a certiﬁed
laboratory. Glomerular ﬁltration rate was calculated using
the Modiﬁcation of Diet in Renal Disease Study Group
formula [13]. For measurement of ADMA, SDMA, and L-
arginine, plasma was subjected to cation exchange solid-
phase extraction and analyzed by high-performance liquid
chromatography [14, 15]. The coeﬃcients of variation for
inter- and intra-assay variations tested with a pooled plasma
sample were <3% for all analytes. The detection limit for
dimethylarginines was 0.04μmol/L.
2.2. Statistics. Continuous data are presented as medians
(interquartile range). Categorical data are given as counts
(%). Mann-Whitney U test was applied for univariate com-
parison of continuous data and Spearman rank correlation
for assessment of associations between continuous variables.
Skewed variables were log-transformed for regression analy-
ses. Univariate and multivariate logistic regression analysis
including diabetic retinopathy as dependent variable and
log-transformed ADMA as well as possible confounders as
independentvariableswasused.ToassesstheeﬀectofADMA
on the prevalence of diabetic retinopathy, odds ratios (OR)
and 95% conﬁdence intervals (95% CI) for a 1 standard
deviation (SD) increment in log-transformed ADMA were
calculated. Variables associated with ADMA and diabetic
retinopathy including the presence of macrovascular disease
were treated as possible confounders in the regression analy-
sis. Age and sex were excluded from the logistic regression
analysis that included GFR, because these variables are
already used in the MDRD formula. A two-sided P<. 05
was considered as statistically signiﬁcant. Calculations were
performed with SPSS for Windows (Version 16.0; SPSS,
Chicago, Ill).
3.Results
The characteristics of the study population are presented in
Table 1. Importantly, the proportion of patients with and
without macrovascular disease was comparable in patients
with and without diabetic retinopathy. Patients with diabetic
retinopathy had signiﬁcantly higher levels of ADMA and
SDMAcompared to those without. L-arginine was compara-
blebetweenthegroups.Inaddition,thesepatientshadlonger
diabetes duration, lower GFR, and higher HDL-cholesterol.
They were less likely to be smokers and tended to be older
than patients without retinopathy (Table 1).
ADMA did not diﬀer signiﬁcantly between women
and men (0.61 (0.52–0.93)μmol/L versus 0.59 (0.50–
0.68)μmol/L; P = .207) as well as smokers and non-
smokers (0.58 (IQR: 0.50–0.76)μmol/L versus 0.58 (0.49–
0.69)μmol/L; P = .568). ADMA was signiﬁcantly related toCardiology Research and Practice 3
Table 1: Characteristics, L-Arginine, and asymmetric and symmetric dimethylarginine according to the prevalence of diabetic retinopathy.
No retinopathy Retinopathy P value
N 60 67
Female 19 (31.7%) 30 (44.8%) .130
Proliferative retinopathy 32 (47.8%)
Macrovascular Disease 30 (50.0%) 38 (56.7%) .449
Smokers 25 (42.4%) 10 (19.2%) .009
Age (years) 62 (54–69) 64 (56–73) .051
Diabetes duration (years) 9 (4–16) 14 (10–17) .027
HbA1c (%) 8.0 (7.0–9.0) 7.4 (7.0–8.1) .127
Body mass index (kg/m2) 29.2 (26.4–32.3) 29.7 (25.8–34.2) .529
Systolic blood pressure (mmHg) 141 (134–157) 144 (129–163) .891
Diastolic blood pressure (mmHg) 83 (77–90) 80 (73–91) .164
Total cholesterol (mg/dL) 188 (157–213) 193 (164–218) .686
LDL cholesterol (mg/dL) 94 (74–129) 90 (69–116) .300
HDL cholesterol (mg/dL) 44 (36–50) 50 (43–56) .020
Triglycerides (mg/dL) 175 (115–265) 194 (147–284) .276
Glomerular ﬁltration rate (mL/min/1.73m2) 79 (59–100) 59 (43–78) <.001
L-Arginine (μmol/L) 74 (62–94) 82 (63–119) .359
Asymmetric dimethylarginine (μmol/L) 0.55 (0.48–0.67) 0.62 (0.53–0.96) .011
Symmetric dimethylarginine (μmol/L) 0.49 (0.43–0.63) 0.61 (0.48–0.92) .005
Categorical variables are presented as counts (%) and continuous variables are presented as medians (interquartile range); the χ2-test and Mann-Whitney
Ut e s thave been applied for comparisons between the groups.
SDMA, L-arginine, age, diabetes duration, and glomerular
ﬁltration rate in the whole study cohort. No association
between ADMA and other clinical parameters could be
observed (Table 2).
The univariate logistic regression analysis showed that
ADMA was signiﬁcantly associated with the prevalence of
diabetic retinopathy before and after adjusting for macrovas-
cular disease. However, including age and sex into the
multivariate model raised the P-level of this association
above the level of signiﬁcance. Multivariate adjustment for
prevalence of macrovascular disease, diabetes duration, and
GFR completely abolished the association between ADMA
and diabetic retinopathy (Table 3).
Because of the signiﬁcant independent association
between GFR and diabetic retinopathy, a secondary analysis
including GFR as dependent variable was performed. GFR
was signiﬁcantlyrelated toSDMA,L-arginine, diabetesdura-
tion, and HbA1c (Table 4). GFR was comparable between
womenandmen(60(52–86)mL/min/1.73m2 versus72(52–
93)mL/min/1.73m2; P = .255) as well as smokers and
nonsmokers (72 (43–72)mL/min/1.73m2 versus 67 (53–
90)mL/min/1.73m2; P = .697). Both the univariate and
multivariate logistic regression models showed that GFR was
the only parameter independently related to the prevalence
of diabetic retinopathy (Table 5).
4.Discussion
The results of the present study show that circulating
ADMA is related to diabetic retinopathy independently of
macrovascular disease. These ﬁndings do not conﬁrm the
Table 2: Spearman correlations of ADMA with other variables.
ρP value
Age 0.189 .033
Diabetes duration 0.190 .048
HbA1c −0.079 .412
Body mass index 0.016 .870
Systolic blood pressure −0.133 .172
Diastolic blood pressure −0.183 .060
Total cholesterol −0.068 .539
LDL cholesterol −0.040 .727
HDL cholesterol 0.024 .830
Triglycerides −0.141 .203
Glomerular ﬁltration rate −0.347 <.001
L-Arginine 0.548 <.001
Symmetric dimethylarginine 0.633 <.001
hypothesis that this association is independent of other
possible confounders. Interestingly, GFR was shown to be
the only independent predictor for the prevalenceof diabetic
retinopathy in this cross-sectional analysis.
The ﬁnding that ADMA is not independently related to
diabetic retinopathy in patients with T2DM was surprising
regarding the recently published data by Malecki et al. [8].
Nevertheless this study missed to evaluate the prevalence
of macrovascular disease which would be important. This
shortfall could introduce bias, as ADMA is known to be
related to macrovascular disease [4]. Macrovascular disease
itself has been shown to be related to diabetic retinopathy4 Cardiology Research and Practice
Table 3: Univariate and multivariate logistic regression analysis including diabetic retinopathy as dependent variable and asymmetric
dimethylarginine (ADMA) and possible confounders as independent variables.
Odds ratio (95% CI) P value
Univariate model ADMA (per 1 SD log increase) 1.50 (1.03–2.17) .034
Multivariate model 1 ADMA (per 1 SD log increase) 1.48 (1.02–2.15) .039
MVD versus no MVD 1.22 (0.60–2.50) .581
Multivariate model 2
ADMA (per 1 SD log increase) 1.36 (0.93–2.00) .113
Age 1.04 (1.00–1.07) .078
Sex (male versus female) 0.70 (0.33–1.52) .370
MVD versus no MVD 1.27 (0.61–2.64) .522
Multivariate model 3
ADMA (per 1 SD log increase) 1.17 (0.73–1.90) .518
DM2 duration (per 1 SD log increase) 1.27 (0.80–2.01) .306
GFR (per 10mL/min/1.73m2 decrease) 1.30 (1.08–1.56) .006
MVD versus no MVD 0.88 (0.37–2.10) .774
GFR: glomerular ﬁltration rate calculated with the MDRD formula; 95% CI: 95% conﬁdence interval; DM2: diabetes mellitus type 2; MVD: macrovascular
disease.
Table 4: Spearman correlations of GFR with other variables.
ρP value
Diabetes duration −0.266 .006
HbA1c 0.307 .001
Body mass index 0.085 .402
Systolic blood pressure −0.017 .862
Diastolic blood pressure 0.247 .011
Total cholesterol 0.077 .492
LDL cholesterol 0.128 .268
HDL cholesterol −0.136 .233
Triglycerides 0.060 .590
L-Arginine −0.252 .005
Symmetric dimethylarginine −0.684 <.001
as shown by Reaven et al. [16]. For this reason, the present
investigation includedpatients with and without retinopathy
who were carefully selected with regard to the prevalence of
macrovascular disease. Nearly equal proportions of patients
had macrovascular disease in the groups with and with-
out retinopathy. Macrovascular disease was not a major
confounder and did not abolish the signiﬁcant association
between ADMA and retinopathy in the multivariate regres-
sion analysis. These results diﬀer from those reported by
Malecki et al. due to the eﬀects of sex, age, and GFR that
eliminated the signiﬁcant relationship between retinopathy
and ADMA. GFR was the best independent predictor for
the prevalence of retinopathy in our study. Interestingly, cal-
culated creatinine clearance did not diﬀer between patients
with and without retinopathy in the study by Malecki et al.
which included diabetic subjects with better renal function
[8]. Only 22 patients had GFR > 90mL/min/1.73m2 in the
present study. It is possible that ADMA is independently
related to retinopathy only in patients with normal renal
function. The notion that moderate renal failure leads to
a signiﬁcant ADMA increase [17] could at least partly
explain the discrepancies between the reported ﬁndings. In
addition, our study included 32 patients with T2DM and
proliferative retinopathy, which reﬂects more prevalence of
serious microvascular disease compared with the study pop-
ulation investigated by Malecki et al., which included only
3 patients with proliferative retinopathy [8]. Proliferative
diabetic retinopathy and impaired renal function are often
interrelated in patients with T2DM [18, 19]. These ﬁndings
and the fact that both study cohorts diﬀered substantially
regarding the included number of patients with proliferative
retinopathy provide another potential explanation for the
discrepant results between the studies. In a large number
of patients with type 1 diabetes, Tarnow et al. [5]d i d
not observe a relationship between ADMA and simplex
or proliferative diabetic retinopathy, ﬁndings which are in
accordancewithourresultsobtainedinpatientswithT2DM.
Nevertheless, the divergent ﬁndings on circulating
ADMA and diabetic retinopathy do not exclude a patho-
physiologic role of ADMA for the development of diabetic
retinopathy. As published by Sugai et al., evidence exists
that ADMA concentrations in aqueous humor are associated
with severe diabetic retinopathy. Nevertheless, it was also
mentioned in this report that ADMA concentrations found
in aqueous humor are not related to circulating ADMA [20].
This could be another explanation why circulating ADMA
was not associated with diabetic retinopathy. Intraocular
but not circulating ADMA might be of pathophysiologic
relevance for diabetic retinopathy.
From the present data, it could be assumed that renal
dysfunction, which is often found in patients with T2DM,
is an important factor associated with diabetic retinopathy.
This is in line with ﬁndings from previous studies, which
showed a signiﬁcant and independent association between
retinopathy and declining renal function in T2DM. More-
over, it was shown that diabetic retinopathy can predict
the deterioration of renal function [21, 22]. This suggests
that reduced GFR rather appears after than before the
development of retinopathy. As GFR signiﬁcantly inﬂuencesCardiology Research and Practice 5
Table 5: Univariate and multivariate logistic regression analysis including diabetic retinopathy as dependent variable and glomerular ﬁltra-
tion rate (GFR) and possible confounders as independent variables.
Odds ratio (95% CI) P value
Univariate model GFR (10mL/min/1.73m2 decrease) 1.32 (1.13–1.54) .001
Multivariate model
GFR (10mL/min/1.73m2 decrease) 1.30 (1.08–1.56) .006
ADMA (per 1 SD log increase) 1.17 (0.73–1.90) .518
DM2 duration (per 1 SD log increase) 1.27 (0.80–2.01) .306
MVD versus no MVD 0.88 (0.37–2.10) .881
GFR: glomerular ﬁltration rate calculated with the MDRD formula; 95% CI: 95% conﬁdence interval; DM2, diabetes mellitus type 2.
circulatingADMA,itislikelythatelevatedADMAinpatients
with diabetic retinopathy appeared after the emergence of
diabetic retinopathy in our study cohort.
The present investigation is limited by the cross-sectional
study design which does not allow statements on causality.
The strength of the present study design is the high
prevalence of macrovascular disease in patients with and
without retinopathy. This allowed the evaluation of the
eﬀect of macrovascular disease on the relationship between
ADMA and diabetic retinopathy. Although no independent
relationship between ADMA and the prevalence of diabetic
retinopathy could be detected in this study, a pathophysi-
ological link between ADMA, impaired renal function, and
diabetic retinopathy cannot be excluded. Further studies are
needed to evaluate the inﬂuence of ADMA on microvascular
complication.
5.Conclusion
In conclusion, this study demonstrated that ADMA is
associated with retinopathy in patients with T2DM inde-
pendent of macrovascular disease. This eﬀect is substantially
modiﬁed by adjusting for GFR which remained the single
independent parameter related to diabetic retinopathy in
a logistic regression analysis. Our ﬁndings cannot support
the hypothesis that circulating ADMA is independently
associated with diabetic retinopathy but do not exclude that
ADMA lies in the causative path between renal dysfunction
and diabetic retinal disease.
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